How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

946 results for

Anxiety Non-pharmacologic Management

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Presurgery Anxiolysis in Children Treated With Hydroxyzine Versus Non-pharmacological Intervention (Distractoria Technique Clown)

Presurgery Anxiolysis in Children Treated With Hydroxyzine Versus Non-pharmacological Intervention (Distractoria Technique Clown) Presurgery Anxiolysis in Children Treated With Hydroxyzine Versus Non-pharmacological Intervention (Distractoria Technique Clown) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Presurgery Anxiolysis in Children Treated With Hydroxyzine Versus Non-pharmacological Intervention (Distractoria Technique Clown) (SONRISA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2017 Clinical Trials

62. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine

Resource implications The dosage of carbamazepine in the studies was usually 300-400 mg daily. The cost (excluding VAT) of 1 months' treatment with carbamazepine 400 mg daily ranges from £5.20 to £27.16 depending on the formulation (Drug T ariff, January 2015). Introduction and current guidance The NICE/SCIE guideline on dementia recommends non-pharmacological interventions tailored to the individual person's preferences, skills and abilities as first-line treatment. People who develop non-cognitive (...) Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine Management of aggression, agitation and Management of aggression, agitation and beha behaviour vioural disturbances in dementia: al disturbances in dementia: carbamazepine carbamazepine Evidence summary Published: 10 March 2015 nice.org.uk/guidance/esuom40 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in March 2015. See summaries

2015 National Institute for Health and Clinical Excellence - Advice

63. Clinical Practice Guideline on the Management of Osteoarthritis of the Hip

Clinical Practice Guideline on the Management of Osteoarthritis of the Hip MANAGEMENT OF OSTEOARTHRITIS OF THE HIP EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE Adopted by the American Academy of Orthopaedic Surgeons Board of Directors 3.13.17 Endorsed by: 1 Disclaimer This Clinical Practice Guideline was developed by an AAOS physician volunteer Guideline development group based on a systematic review of the current scientific and clinical information and accepted approaches to treatment (...) Criteria in a User-Friendly Format, Please Visit the Orthoguidelines Web-Based App at www.orthoguidelines.org or by clicking the icon above! 3 SUMMARY OF RECOMMENDATIONS The following is a summary of the recommendations of the AAOS Clinical Practice Guideline on the Management of Osteoarthritis of the Hip. All readers of this summary are strongly urged to consult the full guideline and evidence report for this information. We are confident that those who read the full guideline and evidence report

2017 American Academy of Orthopaedic Surgeons

64. Managing Chronic Non-Terminal Pain in Adults Including Prescribing Controlled Substances

in an independent home exercise program. An ergonomic work site evaluation and consultation with an occupational medicine specialist should be considered in patients who are disabled from work. Patients with continued pain and disability should be referred to a musculoskeletal specialist (e.g., orthopedic surgeon, rheumatologist, physiatrist, sports medicine specialist). Osteoarthritis. Optimal medical management of osteoarthritis consists of non-pharmacologic measures and pharmacologic treatment. Non (...) analgesia is not possible for many patients. • Expectations. Patient and provider expectations should be articulated clearly at the beginning of treatment and reviewed regularly. A written controlled substance treatment agreement is appropriate for most patients treated with ongoing daily opioid therapy. [1D]* • Non-pharmacologic therapies. Begin with these therapies (e.g., exercise, heat, sleep hygiene). • Medical treatment. Choose drugs based on presumed pain type and the patient’s comorbidities

2017 University of Michigan Health System

65. Crisis Intervention for Adults Using a Trauma-Informed Approach: Initial Four Weeks of Management Third Edition

of Management — Third Edition Topics Outside the Scope of This Guideline The following topics are not covered within this Guideline: ? in-depth recommendations beyond the fourth week of crisis interventions, ? crisis among children and youth (less than 18 years of age), ? screening and assessment criteria for crisis intervention, and ? pharmacological treatment options for crisis. For guidance on topics outside the scope of this Guideline, please refer to Appendix D. For more information regarding (...) Crisis Intervention for Adults Using a Trauma-Informed Approach: Initial Four Weeks of Management Third Edition DECEMBER 2017 Crisis Intervention for Adults Using a Trauma-Informed Approach: Initial Four Weeks of Management Third Edition Best Practice GuidelinesDisclaimer These guidelines are not binding on nurses, other providers of the interprofessional team, or the organizations that employ them. The use of these guidelines should be flexible, and based on individual needs and local

2017 Registered Nurses' Association of Ontario

66. BSR guideline Management of Adults with Primary Sjögren's Syndrome (Full text)

therapy and immunomodulatory treatment. Holistic management is important and many patients benefit from non-pharmacological therapies and general support. Diagnosis Patients commonly present with dryness of the eyes [ ] and mouth [ ]. In the early stages they may complain of grittiness rather than dryness of the eyes, and the mouth symptoms may require prompting. Fatigue and arthralgia are almost universal. There is often a considerable delay between symptom onset and diagnosis. The most widely (...) Anwar Tappuni, Reader and Academic Lead for Oral Medicine, was the main contributor to the oral section and Dr Nurhan Sutcliffe, Consultant Rheumatologist, acted as the lead for the systemic section. Ms Katie L. Hackett was the British Health Professionals in Rheumatology’s representative and lead for non-pharmacological management. Dr Francesca Barone, Clinician Scientist and Honorary Consultant Rheumatologist, was the lead for the Delphi process and supervised Dr Guido Granata, Visiting Fellow

2017 British Society for Rheumatology PubMed abstract

67. Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease

in patients with diabetes and CKD stages 4 and 5 28 Management of hyperkalaemia with RAAS blockade in patients with diabetes and CKD stages 4 and 5 29 Non-pharmacological management of hypertension in patients with diabetes and CKD stages 4 and 5 30 4 Hypertension management in patients with diabetes and chronic kidney disease who are on dialysis (stage 5D) 31 Recommendations 32 Audit standards 32 Areas that require further research 33 Introduction 33 Blood pressure measurement in patients with diabetes (...) and specialists in diabetes, cardiology and nephrology. It intends to harmonise practices of blood pressure monitoring, and pharmacological and non-pharmacological management of hypertension, which may vary considerably. Evidence grades for the recommendations The following evidence grading has been used to determine the strength of the recommendations; the suggested audit standards; and the questions for areas that require future research. 1A – Strong recommendation: high-quality evidence 1B – Strong

2017 Association of British Clinical Diabetologists

68. High Blood Pressure in Adults: Guideline For the Prevention, Detection, Evaluation and Management

, ACPM, AGS, APhA, ASH, ASPC, NMA, and PCNA. 1.4. Scope of the Guideline The present guideline is intended to be a resource for the clinical and public health practice communities. It is designed to be comprehensive but succinct and practical in providing guidance for prevention, detection, evalu- ation, and management of high BP. It is an update of the NHLBI publication, “The Seventh Report of the Joint National Committee on Prevention, Detection, Evalua- tion and Treatment of High Blood Pressure (...) High Blood Pressure in Adults: Guideline For the Prevention, Detection, Evaluation and Management CLINICAL PRACTICE GUIDELINE 2017 ACC/AHA/AAPA/ABC/ACPM/ AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection,Evaluation,andManagement of High Blood Pressure in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Writing Committee Members Paul K. Whelton, MB, MD, MSC, FAHA, Chair Robert M. Carey, MD, FAHA, Vice

2017 American College of Cardiology

69. Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation

of such practice, the data provide a useful insight into the clinical management of acute disturbance in mental health services in the UK. In the vast majority of episodes (n = 2061; 95%), one or more non-pharmacological interventions were employed. Predominantly, these were de-escalation strategies (verbal de- escalation and/or distraction and/or removal of precipitating factors), control and restraint, or observation. Control and restraint was approximately three times more likely to be used in association (...) - tion (Royal College of Psychiatrists, 2014), recommendations on the use of licensed medication in unlicensed situations (Royal College of Psychiatrists Psychopharmacology Committee, 2017), and prescribing guidance for unlicensed medicines by the General Medical Council (GMC, 2013). International perspectives The most recent comprehensive review of the evidence base for the management of acute disturbance is a consensus document produced by the World Federation of Societies for Biological Psychiatry

2018 British Association for Psychopharmacology

70. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope (Full text)

by the governing bodies of the ACC, AHA, and HRS and was endorsed by the American College of Emergency Physicians, the Society for Academic Emergency Medicine, and the Pediatric and Congenital Electrophysiology Society. 1.4. Scope of the Guideline The purpose of this ACC/AHA/HRS guideline is to provide contemporary, accessible, and succinct guidance on the management of adult and pediatric patients with suspected syncope. This guideline is intended to be a practical document for cardiologists, arrhythmia (...) adults by a different age cutoff, the relevant age is noted in those specific cases. Finally, the guideline addresses the management of syncope with the patient as a focus, rather than larger aspects of health services, such as syncope management units. The goals of the present guideline are: To define syncope as a symptom, with different causes, in different populations and circumstances. To provide guidance and recommendations on the evaluation and management of patients with suspected syncope

2017 American Heart Association PubMed abstract

71. Syncope: Guideline For Evaluation and Management of Patients With

Syncope: Guideline For Evaluation and Management of Patients With CLINICAL PRACTICE GUIDELINE 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society Developed in Collaboration With the American College of Emergency Physicians and Society for Academic Emergency Medicine Endorsed by the Pediatric and Congenital (...) : Recommendations .. . e59 3.3. Neurological Testing: Recommendations . e60 3.3.1. AutonomicEvaluation:Recommendation.. e60 3.3.2. Neurological and Imaging Diagnostics: Recommendations e61 4.MANAGEMENT OF CARDIOVASCULAR CONDITIONS e62 4.1. Arrhythmic Conditions: Recommendations .. .. e62 4.1.1. Bradycardia: Recommendation ... e62 4.1.2. Supraventricular Tachycardia: Recommendations .. ... e63 4.1.3. Ventricular Arrhythmia: Recommendation ... ... e63 4.2. Structural Conditions: Recommendations ... .. e63 4.2.1

2017 American College of Cardiology

72. Management of Opioid Therapy (OT) for Chronic Pain

, particularly overdose and OUD, often far outweigh the potential benefits. As such, in accounting for all four domains, these factors contributed to Strong recommendations in multiple instances. # Recommendation Strength* Category† Initiation and Continuation of Opioids 1. a) We recommend against initiation of long-term opioid therapy for chronic pain. b) We recommend alternatives to opioid therapy such as self- management strategies and other non-pharmacological treatments. c) When pharmacologic therapies (...) represent a clinical state or condition. Hexagons represent a decision point in the guideline, formulated as a question that can be answered Yes or No. Rectangles represent an action in the process of care. V A / D o D Cli ni cal P r a cti ce G ui d el i n e f o r O p ioid T h e r a p y for Ch r on ic Pa in February 2017 Page 11 of 198 A. Module A: Determination of Appropriateness for Opioid Therapy Note: Non-pharmacologic and non-opioid pharmacologic therapies are preferred for chronic pain. V A / D o

2017 VA/DoD Clinical Practice Guidelines

73. Management of Diabetes Mellitus in Primary Care

Practice Guideline 8 A. Methods 8 B. Summary of Patient Focus Group Methods and Findings 12 C. Conflict of Interest 13 D. Scope of this Clinical Practice Guideline 14 E. Highlighted Features of this Clinical Practice Guideline 15 F. Shared Decision-making and Patient-centered Care 15 G. Implementation 16 IV. Guideline Work Group 17 V. Algorithm 18 A. Algorithm 19 VI. Recommendations 21 A. General Approach to T2DM Care 23 B. Glycemic Control Targets and Monitoring 28 C. Non-pharmacological Treatments 36 (...) vascular disease.[13] In addition to the complications of T2DM, conditions such as chronic obstructive pulmonary disease (COPD), substance use disorder (SUD), and depression can affect the management of DM. For guidance on how to address those comorbidities, see the respective VA/DoD Clinical Practice Guidelines for the Management of COPD, SUD and Major Depressive Disorder (MDD). 2,3,4 DM is a major cause of morbidity and mortality in the U.S. It is associated with a two-fold to four-fold increased

2017 VA/DoD Clinical Practice Guidelines

74. Management of Posttraumatic Stress Disorder and Acute Stress Reaction

Disorder with Co-occurring Conditions 72 VII. Knowledge Gaps and Recommended Research 76 A. Shared Decision Making and Collaborative Care 76 B. Treatments for Acute Stress Disorder and Preventing Posttraumatic Stress Disorder 76 VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder June 2017 Page 4 of 200 C. Treatments for Posttraumatic Stress Disorder 76 D. Non-Pharmacologic Biological Treatments for Posttraumatic Stress Disorder 78 E (...) Management of Posttraumatic Stress Disorder and Acute Stress Reaction VA/DOD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF POSTTRAUMATIC STRESS DISORDER AND ACUTE STRESS DISORDER Department of Veterans Affairs Department of Defense QUALIFYING STATEMENTS The Department of Veterans Affairs and the Department of Defense guidelines are based upon the best information available at the time of publication. They are designed to provide information and assist decision making. They are not intended

2017 VA/DoD Clinical Practice Guidelines

75. Multiple sclerosis in adults: management

Multiple sclerosis in adults: management Multiple sclerosis in adults: management Multiple sclerosis in adults: management Clinical guideline Published: 8 October 2014 nice.org.uk/guidance/cg186 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available (...) after diagnosis with significant impact on their ability to work, as well as an adverse and often highly debilitating effect on their quality of life and that of their families. This guideline replaces NICE clinical guideline 8 (2003) and covers diagnosis, information and support, treatment of relapse and management of MS-related symptoms. The guideline does not address all symptoms and problems associated with MS. Some areas are addressed in other NICE guidance for example urinary symptoms

2014 National Institute for Health and Clinical Excellence - Clinical Guidelines

76. Atrial fibrillation: management

treatments include anticoagulants to reduce the risk of stroke and antiarrhythmics to restore or maintain the normal heart rhythm or to slow the heart rate in people who remain in atrial fibrillation. Non-pharmacological management includes electrical cardioversion, which may be used to 'shock' the heart back to its normal rhythm, and catheter or surgical ablation to create lesions to stop the abnormal electrical impulses that cause atrial fibrillation. This updated guideline addresses several clinical (...) Atrial fibrillation: management Atrial fibrillation: management Atrial fibrillation: management Clinical guideline Published: 18 June 2014 nice.org.uk/guidance/cg180 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement

2014 National Institute for Health and Clinical Excellence - Clinical Guidelines

77. Guidance on the clinical management of depressive and bipolar disorders, specifically focusing on diagnosis and treatment strategies

Guidance on the clinical management of depressive and bipolar disorders, specifically focusing on diagnosis and treatment strategies First published in Australian and New Zealand Journal of Psychiatry 2015, Vol. 49(12) 1-185. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Gin S Malhi 1,2 , Darryl Bassett 3,4 , Philip Boyce 5 , Richard Bryant 6 , Paul B Fitzgerald 7 , Kristina Fritz 8 , Malcolm Hopwood 9 , Bill Lyndon 10,11,12 , Roger (...) Mulder 13 , Greg Murray 14 , Richard Porter 13 and Ajeet B Singh 15 Abstract Objectives: To provide guidance for the management of mood disorders, based on scientific evidence supplemented by expert clinical consensus and formulate recommendations to maximise clinical salience and utility. Methods: Articles and information sourced from search engines including PubMed and EMBASE, MEDLINE, PsycINFO and Google Scholar were supplemented by literature known to the mood disorders committee (MDC) (e.g

2015 Royal Australian and New Zealand College of Psychiatrists

78. Autism in under 19s: support and management

following consultation with a specialist paediatrician or psychiatrist with expertise in the management of autism or paediatric sleep medicine be used in conjunction with non-pharmacological interventions be regularly reviewed to evaluate the ongoing need for a pharmacological intervention and to ensure that the benefits continue to outweigh the side effects and risks. 1.7.8 If the sleep problems continue to impact on the child or young person or their parents or carers, consider: referral (...) Autism in under 19s: support and management Autism spectrum disorder in under 19s: Autism spectrum disorder in under 19s: support and management support and management Clinical guideline Published: 28 August 2013 nice.org.uk/guidance/cg170 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

79. Non-pharmacological Interventions for Behavioral Symptoms of Dementia

, studies were generally limited by small sample size and poor quality. The limited body of evidence is insufficient to draw definitive conclusions about the effects of bright light therapy in managing sleep, behavior, or mood disturbances associated with dementia.3 Non-pharmacological Interventions for Behavioral Symptoms of Dementia Evidence-based Synthesis Program Massage and Touch: Massage and touch therapies aim to reduce depression, anxiety, and other behavioral symptoms of dementia. A systematic (...) Transcutaneous Electrical Nerve Stimulation 18 Behavior Management Techniques 19 Other Psychosocial Interventions 24 Animal-assisted Therapy 24 Exercise 27 Various Interventions Targeting a Specific Behavioral Symptom 29 Wandering 29 Agitation 30 Inappropriate Sexual Behavior 31 Comparative Effectiveness among Non-pharmacological Interventions and between Pharmacological and Non-pharmacological Approaches 31 iii Non-pharmacological Interventions for Behavioral Symptoms of Dementia Evidence-based Synthesis

2011 Veterans Affairs Evidence-based Synthesis Program Reports

80. CRACKCast E112 – Anxiety Disorders

behaviour leading to self-harm or harm to others Prevent end-organ dysfunction Improve patient comfort and satisfaction [7] List 6 non-pharmacologic therapies for anxiety Reduction of environmental stimulants (quiet, private room) Dimming of lights, with music/aromatherapy Collateral help from family, social worker Breathing techniques Avoidance of caffeine and EtOH Psychotherapy High intensity, supervised exercise Because anxiety states cause an increase in metabolic demands, they can cause (...) , obtrusive, unwanted thoughts (obsessions), such as fears of contamination, or compulsive behaviors or mental acts (compulsions) that a person feels compelled to perform, such as hand-washing or counting Generalized Anxiety Disorder (GAD) GAD is defined as excessive worry that occurs most days over a 6-month period involving several events or activities. The anxiety must cause significant distress or impairment in functioning. [6] List ED management goals for patients with anxiety Avoid escalating

2017 CandiEM

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>